10 January 2023
Drug reviews and drug licensing
Showing results 11 - 20 of 100
Sorted by most recent
21 December 2022
27 October 2022
11 October 2022
28 July 2022
30 June 2022
29 June 2022
26 April 2022
23 February 2022
11 January 2022
Validation period: 12/21/2024, 8:04:13 AM - 12/22/2024, 8:04:13 AM
Risk of serious adverse effects with Janus kinase inhibitors Safety update: dupilumab and ocular adverse reactions ▼Palforzia for oral desensitisation to peanut in allergic children More concerns over safety of topiramate in pregnancy ▼Bempedoic acid: another cholesterol-lowering drug Safety update: monitoring patients taking amiodarone ▼Inclisiran: more hope less hype Two new oral antivirals for covid-19: ▼molnupiravir and ▼nirmatrelvir plus ritonavir Naldemedine for opioid-induced constipation Dapagliflozin no longer licensed for type 1 diabetes